Glivec and Viral gastroenteritis - a phase IV clinical study of FDA data

Summary:

Viral gastroenteritis is reported as a side effect among people who take Glivec (imatinib mesylate), especially for people who are male, 2-9 old, also take Ambisome, and have Acute lymphocytic leukemia (all).

The phase IV clinical study analyzes which people have Viral gastroenteritis when taking Glivec. It is created by eHealthMe based on reports of 17,769 people who have side effects when taking Glivec from the FDA, and is updated regularly.

What is Glivec?

Glivec has active ingredients of imatinib mesylate. eHealthMe is studying from 17,777 Glivec users. Check the latest studies of Glivec.

What is Viral gastroenteritis?

Viral gastroenteritis is found to be associated with 73 drugs and 344 conditions by eHealthMe. Check the latest studies of Viral gastroenteritis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

17,769 people reported to have side effects when taking Glivec.
Among them, 13 people (0.07%) have Viral gastroenteritis.

Could Glivec cause Viral gastroenteritis?

Among these 13 people:

What is the gender of people who have Viral gastroenteritis when taking Glivec? *

female: 0.0 %
male: 100 %

What is the age of people who have Viral gastroenteritis when taking Glivec? *

What are other drugs people take besides Glivec? *

Ambisome: 8 people, 61.54%

What are other side effects people have besides Viral gastroenteritis? *

Febrile Neutropenia (fever with reduced white blood cells): 13 people, 100.00%
Fever: 13 people, 100.00%
Gastrointestinal Viral Infection (virus infection of gastrointestinal tract): 12 people, 92.31%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 12 people, 92.31%
Anal Inflammation: 12 people, 92.31%
Catheter Site Infection (infection at the site of insertion): 12 people, 92.31%
Drug Hypersensitivity: 12 people, 92.31%
Stomatitis (inflammation of mucous membrane of mouth): 12 people, 92.31%
Upper Respiratory Tract Infection: 12 people, 92.31%
Hypokalemia (low potassium): 12 people, 92.31%

What are the existing conditions these people have? *

Leukaemia (blood or bone marrow cancer): 12 people, 92.31%
Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 12 people, 92.31%

* Approximation only. Some reports may have incomplete information.

Do you take Glivec and have Viral gastroenteritis?

- Check whether Viral gastroenteritis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Glivec:

Glivec (17,777 reports)

Browse all side effects of Glivec:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Viral gastroenteritis:

Viral gastroenteritis (73 drugs)

Browse all the conditions that are associated with Viral gastroenteritis:

Viral gastroenteritis (344 conditions)

Related publications that referenced our studies

O'rafferty C, McElligott F, Storey L, O'marcaigh A, Smith O, "Pneumatosis intestinalis and imatinib mesylate", Annals of hematology, 2014 Oct .
O'rafferty C, McElligott F, Storey L, O'marcaigh A, Smith O, "Pneumatosis intestinalis and imatinib mesylate", Annals of hematology, 2014 Oct .

How the study uses the data?

The study uses data from the FDA. It is based on imatinib mesylate (the active ingredients of Glivec) and Glivec (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.